Anti-diabetic drugs can lower cancer risk by 32%
A specific type of diabetes drug can decrease the risk of cancer in female patients with type 2 diabetes up to 32%, according to a study published in Diabetes, Obesity and Metabolism. People with type 2 diabetes have a higher rate of cancer development and recurrence compared to the general population.
A specific type of diabetes drug can decrease the risk of cancer in female patients with type 2 diabetes up to 32%, according to a study published in Diabetes, Obesity and Metabolism. People with type 2 diabetes have a higher rate of cancer development and recurrence compared to the general population.
A team of Cleveland Clinic researchers led by Sangeeta Kashyap, MD, an endocrinologist and associate professor of medicine at Cleveland Clinic’s Endocrinology & Metabolism Institute, compared two groups of drugs commonly used to treat type 2 diabetes-insulin sensitizers and insulin secretagogues.
Insulin sensitizers lower blood sugar and insulin levels in the body by increasing the muscle, fat, and liver’s response to insulin. Insulin secretagogues lower blood sugar by stimulating pancreatic beta cells to make more insulin.
“What this study shows us is that using insulin secretagogues to increase insulin production correlates with an increased cancer risk in women with type 2 diabetes,” Kashyap said. “By contrast, insulin sensitizers cut insulin levels and can decrease cancer growth. Clearly, when prescribing anti-diabetic medications, it’s important to consider the impact a drug has on fueling cancer growth.”
In a retrospective analysis, researchers cross-indexed the electronic health record-based Cleveland Clinic Diabetes Registry (25,613 patients) with the histology-based tumor registry (48,051 cancer occurrences) over an 8-year period (1998–2006).
More than 890 incident cancer cases were identified. The most common cancers were prostate and breast accounting for more than 25% of total cancer cases. Study results show that the use of insulin sensitizers in female patients with type 2 diabetes was associated with a 21% decreased cancer risk compared with insulin secretagogues.
Furthermore, the use of a specific insulin sensitizer, thiazolidinedione, was associated with a 32% decreased cancer risk in female patients compared with sulphonylurea, an insulin secretagogue. Results showed no significant difference in men.
The findings in this study contribute to existing research in the field on diabetic patients and their increased cancer risk.
